Paul McGarry


Recent Posts

Champions Oncology Granted Full Accreditation by the AAALAC

Aug 8, 2018 8:30:17 AM / by Paul McGarry

Hackensack, NJ – August 8, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.  AAALAC commended Champions for the quality and dedication of the staff, the superior quality of the animal facilities, the excellent program of veterinary medical care, and the highly knowledgeable and conscientious Institutional Animal Care and Use Committee.

Read More →

Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

Jul 27, 2018 9:53:44 AM / by Paul McGarry

Expects Revenue Growth of at Least 20% for Fiscal Year 2019

Hackensack, NJ – July 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2018.

Read More →

Champions Oncology to Present at the 3rd Annual Disruptive Growth & Healthcare Conference on May 9th

May 3, 2018 9:27:54 AM / by Paul McGarry

HACKENSACK, N.J., - May 3, 2018 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith’s offices located at 599 Lexington Avenue.

Read More →

Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research

May 1, 2018 9:31:57 AM / by Paul McGarry

Experienced Scientist to Lead Immuno-Oncology Research, Driving Significant Expansion of Market Opportunity

Hackensack, NJ – May 1, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research.

Read More →

Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House

Apr 3, 2018 9:34:28 AM / by Paul McGarry

Hackensack, NJ – April 3, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.

Read More →

Champions Oncology Reports Quarterly Revenue of $5.1 Million

Mar 16, 2018 11:50:20 AM / by Paul McGarry

Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018

Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.

Read More →

Champions Oncology to Participate at the 30th Annual ROTH Conference

Feb 26, 2018 9:15:48 AM / by Paul McGarry

Hackensack, NJ – February 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings.

Read More →

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Feb 20, 2018 10:38:47 AM / by Paul McGarry

Patients with a rare tumor help drive a novel clinical study developed and launched by the Addario Lung Cancer Medical Institute with Champions Oncology

SAN CARLOS, Calif. and Hackensack, NJ (February 20, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.

Read More →